Foretinib (XL880): c-MET Inhibitor with Activity in Papillary Renal Cell Cancer
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Foretinib (XL880): c-MET Inhibitor with Activity in Papillary Renal Cell Cancer
Authors
Keywords
Papillary renal cell cancer, MET, Foretinib
Journal
Current Oncology Reports
Volume 15, Issue 2, Pages 83-90
Publisher
Springer Nature
Online
2013-02-13
DOI
10.1007/s11912-013-0299-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Incidence and long-term prognosis of papillary compared to clear cell renal cell carcinoma – A multicentre study
- (2012) Sandra Steffens et al. EUROPEAN JOURNAL OF CANCER
- A Phase 2 Trial of Sunitinib in Patients with Advanced Non–clear Cell Renal Cell Carcinoma
- (2012) Nizar M. Tannir et al. EUROPEAN UROLOGY
- Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma
- (2012) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- Histopathology of Surgically Treated Renal Cell Carcinoma: Survival Differences by Subtype and Stage
- (2012) Kirk A. Keegan et al. JOURNAL OF UROLOGY
- Abstract A13: Reduction of tumor invasiveness and metastasis and prolongation of survival of RIP-Tag2 mice after inhibition of VEGFR plus c-Met by XL184
- (2012) B. Sennino et al. MOLECULAR CANCER THERAPEUTICS
- MET: a promising anticancer therapeutic target
- (2012) Solange Peters et al. Nature Reviews Clinical Oncology
- Phase II, Multicenter, Uncontrolled Trial of Single-agent Capecitabine in Patients With Non-clear Cell Metastatic Renal Cell Carcinoma
- (2011) Ilya Tsimafeyeu et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma
- (2011) Hung Huynh et al. ANGIOGENESIS
- VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer
- (2011) W.-K. You et al. CANCER RESEARCH
- MiR-1 Downregulation Cooperates with MACC1 in Promoting MET Overexpression in Human Colon Cancer
- (2011) C. Migliore et al. CLINICAL CANCER RESEARCH
- Foretinib (GSK1363089), an Orally Available Multikinase Inhibitor of c-Met and VEGFR-2, Blocks Proliferation, Induces Anoikis, and Impairs Ovarian Cancer Metastasis
- (2011) M. Zillhardt et al. CLINICAL CANCER RESEARCH
- Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks
- (2011) Yu Kataoka et al. INVESTIGATIONAL NEW DRUGS
- Clinical and Pathological Features Associated With Prognosis in Patients With Papillary Renal Cell Carcinoma
- (2011) William R. Sukov et al. JOURNAL OF UROLOGY
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
- (2011) Brian I Rini et al. LANCET
- Synergistic Effects of Foretinib with HER-Targeted Agents in MET and HER1- or HER2-Coactivated Tumor Cells
- (2011) L. Liu et al. MOLECULAR CANCER THERAPEUTICS
- Hereditary kidney cancer
- (2010) W. Marston Linehan et al. CANCER
- Cytogenetic features, clinical significance and prognostic impact of type 1 and type 2 papillary renal cell carcinoma
- (2010) Alessandro Antonelli et al. CANCER GENETICS AND CYTOGENETICS
- A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2
- (2010) J. P. Eder et al. CLINICAL CANCER RESEARCH
- A Comparison of the pharmacokinetics of the anticancer MET inhibitor foretinib free base tablet formulation to bisphosphate salt capsule formulation in patients with solid tumors
- (2010) Aung Naing et al. INVESTIGATIONAL NEW DRUGS
- Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma
- (2010) Ana M. Molina et al. INVESTIGATIONAL NEW DRUGS
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- (2010) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Development and External Validation of a Nomogram Predicting Disease Specific Survival After Nephrectomy for Papillary Renal Cell Carcinoma
- (2010) Tobias Klatte et al. JOURNAL OF UROLOGY
- Histological Subtype is an Independent Predictor of Outcome for Patients With Renal Cell Carcinoma
- (2010) Bradley C. Leibovich et al. JOURNAL OF UROLOGY
- Inhibition of Tumor Cell Growth, Invasion, and Metastasis by EXEL-2880 (XL880, GSK1363089), a Novel Inhibitor of HGF and VEGF Receptor Tyrosine Kinases
- (2009) F. Qian et al. CANCER RESEARCH
- Cytogenetic and Molecular Tumor Profiling for Type 1 and Type 2 Papillary Renal Cell Carcinoma
- (2009) T. Klatte et al. CLINICAL CANCER RESEARCH
- Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer
- (2009) J. P. Eder et al. CLINICAL CANCER RESEARCH
- Phase II Trial of Carboplatin and Paclitaxel in Papillary Renal Cell Carcinoma
- (2009) Kathryn A. Bylow et al. Clinical Genitourinary Cancer
- Is there a Role of the Histologic Subtypes of Papillary Renal Cell Carcinoma as a Prognostic Factor?
- (2009) J. H. Ku et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Erlotinib in Patients With Locally Advanced or Metastatic Papillary Histology Renal Cell Cancer: SWOG S0317
- (2009) Michael S. Gordon et al. JOURNAL OF CLINICAL ONCOLOGY
- Trisomy 7 and 17 mark papillary renal cell tumours irrespectively of variation of the phenotype
- (2009) I Balint et al. JOURNAL OF CLINICAL PATHOLOGY
- Effect of temsirolimus versus interferon-α on outcome of patients with advanced renal cell carcinoma of different tumor histologies
- (2009) Janice P. Dutcher et al. MEDICAL ONCOLOGY
- Prognostic factors in a prospective series of papillary renal cell carcinoma
- (2008) Paolo Gontero et al. BJU INTERNATIONAL
- A critical assessment of the prognostic value of clear cell, papillary and chromophobe histological subtypes in renal cell carcinoma: a population-based study
- (2008) Umberto Capitanio et al. BJU INTERNATIONAL
- Analysis of clinicopathologic predictors of oncologic outcome provides insight into the natural history of surgically managed papillary renal cell carcinoma
- (2008) Vitaly Margulis et al. CANCER
- Molecular cancer therapy: Can our expectation be MET?
- (2008) Cristina Migliore et al. EUROPEAN JOURNAL OF CANCER
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
- Drug development of MET inhibitors: targeting oncogene addiction and expedience
- (2008) Paolo M. Comoglio et al. NATURE REVIEWS DRUG DISCOVERY
- Efficacy of Sunitinib and Sorafenib in Metastatic Papillary and Chromophobe Renal Cell Carcinoma
- (2007) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search